02 June 2021
EMA/282226/2021
EMEA/H/C/000280

Public statement

PegIntron

Withdrawal of the marketing authorisation in the European Union

On 21 April 2021, the European Commission withdrew the marketing authorisation for PegIntron (peginterferon alfa-2b) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Merck Sharp & Dohme B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

PegIntron was granted marketing authorisation in the EU on 25 May 2000 for the treatment of chronic hepatitis C. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2005. It was then granted unlimited validity in 2010.

The European Public Assessment Report (EPAR) for PegIntron will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union